You are here

Heart Drug Serelaxin Gets ‘Breakthrough’ Status

Hormone treats acute heart failure (June 21)

The FDA has granted “breakthrough therapy” status to serelaxin (RLX030, Novartis), an investigational treatment for patients with acute heart failure (AHF). The agency concluded that serelaxin qualifies for the designation after considering the available clinical evidence, which indicates substantial improvement over currently available therapies for AHF, a life-threatening illness.

The FDA’s decision was supported by efficacy and safety results from the phase III RELAX-AHF trial, which also showed that patients who received serelaxin had a 37% reduction in mortality at 6 months after an AHF episode compared with those who received conventional treatment.

Each year, approximately 3.5 million AHF episodes occur in the U.S. and Europe; this is expected to increase further as the population ages. Every AHF episode contributes to worsening heart failure and damage to vital organs, such as the heart and kidneys, which decreases the chance of the patient surviving another episode. New treatments are needed that help relieve patients’ symptoms and protect vital organs against damage during an AHF episode, and that have the potential to increase life expectancy in the AHF patient population.

Serelaxin (RLX030) is a form of a naturally occurring hormone (human relaxin-2) that is present in both men and women, although its levels rise in pregnant women to help the body cope with the additional cardiovascular demands during pregnancy. The drug is proposed for administration on admission to the emergency room to patients experiencing an AHF episode and is infused over a 48-hour period, in addition to conventional therapies.

In the RELAX-AHF trial, serelaxin was shown to have both short and longer-term effects, helping patients breathe during and after an AHF episode, and reducing the rate of heart failure worsening.

Source: Novartis; June 21, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time